Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease
Identifieur interne : 002925 ( Main/Exploration ); précédent : 002924; suivant : 002926Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease
Auteurs : G. Fabbrini [États-Unis] ; J. Juncos [États-Unis] ; M. M. Mouradian [États-Unis] ; C. Serrati [États-Unis] ; Chase [États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 1987-04.
Abstract
The contribution of the peripheral and central pharmacokinetic mechanisms of levodopa to the pathogenesis of the motor fluctuations that complicate its long‐term administration was studied in 28 parkinsonian patients. The rate of levodopa clearance from the general circulation, its plasma half‐life, and apparent volume of distribution were indistinguishable between patients with the on‐off or the wearing‐off phenomenon and those with a stable response to levodopa or those who had not been previously treated with levodopa. Peripheral pharmacokinetic factors are thus unlikely to account for the development of these response fluctuations. Conversely, the efficacy half‐time of levodopa differed markedly among the four response groups studied and may provide a quantitative index of central mechanisms that favor the development of the wearing‐off and on‐off phemonena. Although symptom duration was the best predictor of the severity of untreated parkinsonism, levodopa dose correlated best with response half‐time. The wearing‐off phenomenon may primarily reflect the loss of buffering capacity caused by degeneration of the dopamine neurons, while the development of the on‐off phenomenon appears to require additional postsynaptic changes, possibly at the receptor level.
Url:
DOI: 10.1002/ana.410210409
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease</title><author><name sortKey="Fabbrini, G" sort="Fabbrini, G" uniqKey="Fabbrini G" first="G." last="Fabbrini">G. Fabbrini</name></author><author><name sortKey="Juncos, J" sort="Juncos, J" uniqKey="Juncos J" first="J." last="Juncos">J. Juncos</name></author><author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name></author><author><name sortKey="Serrati, C" sort="Serrati, C" uniqKey="Serrati C" first="C." last="Serrati">C. Serrati</name></author><author><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BD1F62EC1AE83B7280C1223055629AB44E681AE3</idno><date when="1987" year="1987">1987</date><idno type="doi">10.1002/ana.410210409</idno><idno type="url">https://api.istex.fr/document/BD1F62EC1AE83B7280C1223055629AB44E681AE3/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002239</idno><idno type="wicri:Area/Main/Curation">001F25</idno><idno type="wicri:Area/Main/Exploration">002925</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease</title><author><name sortKey="Fabbrini, G" sort="Fabbrini, G" uniqKey="Fabbrini G" first="G." last="Fabbrini">G. Fabbrini</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Juncos, J" sort="Juncos, J" uniqKey="Juncos J" first="J." last="Juncos">J. Juncos</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Serrati, C" sort="Serrati, C" uniqKey="Serrati C" first="C." last="Serrati">C. Serrati</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1987-04">1987-04</date><biblScope unit="volume">21</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="370">370</biblScope><biblScope unit="page" to="376">376</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">BD1F62EC1AE83B7280C1223055629AB44E681AE3</idno><idno type="DOI">10.1002/ana.410210409</idno><idno type="ArticleID">ANA410210409</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The contribution of the peripheral and central pharmacokinetic mechanisms of levodopa to the pathogenesis of the motor fluctuations that complicate its long‐term administration was studied in 28 parkinsonian patients. The rate of levodopa clearance from the general circulation, its plasma half‐life, and apparent volume of distribution were indistinguishable between patients with the on‐off or the wearing‐off phenomenon and those with a stable response to levodopa or those who had not been previously treated with levodopa. Peripheral pharmacokinetic factors are thus unlikely to account for the development of these response fluctuations. Conversely, the efficacy half‐time of levodopa differed markedly among the four response groups studied and may provide a quantitative index of central mechanisms that favor the development of the wearing‐off and on‐off phemonena. Although symptom duration was the best predictor of the severity of untreated parkinsonism, levodopa dose correlated best with response half‐time. The wearing‐off phenomenon may primarily reflect the loss of buffering capacity caused by degeneration of the dopamine neurons, while the development of the on‐off phenomenon appears to require additional postsynaptic changes, possibly at the receptor level.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Fabbrini, G" sort="Fabbrini, G" uniqKey="Fabbrini G" first="G." last="Fabbrini">G. Fabbrini</name></region><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name><name sortKey="Juncos, J" sort="Juncos, J" uniqKey="Juncos J" first="J." last="Juncos">J. Juncos</name><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M. M." last="Mouradian">M. M. Mouradian</name><name sortKey="Serrati, C" sort="Serrati, C" uniqKey="Serrati C" first="C." last="Serrati">C. Serrati</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002925 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002925 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BD1F62EC1AE83B7280C1223055629AB44E681AE3
|texte= Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |